

## **BioMedInvest co-leads CHF 17 Million Series A financing of 4-Antibody AG bringing the total Series A financing to CHF 23 Million (\$ 18.5 Million)**

Basel, January 15, 2007

BioMedInvest announces the completion of a CHF 17 Million Series A financing of 4-Antibody AG. This closing was led by new investor Advent Venture Partners (UK), together with existing lead investors BioMedInvest AG (Switzerland) and Life Sciences Partners (The Netherlands). All other existing investors; Grazia Equity (Germany), Mulligan Biocapital (Germany) and several private investors also participated. BioMedInvest led a seed round in 2004. The total financing has been brought to CHF 23 Million (\$ 18.5 Million).

4-Antibody AG is focused on exploiting its 4mAb™ proprietary platform to improve existing antibodies and to discover de-novo fully human antibodies. Proceeds will be used to accelerate the discovery and development of novel therapeutic monoclonal antibodies. "The success of our Series A financing is a recognition of the potential of our proprietary 4mAb™ platform to generate novel fully human antibodies against a broad range of disease targets. We are very pleased to be able to attract Advent Venture Partners, a top tier Life Sciences investor, complementing our existing investor syndicate. We are now well positioned to build on our product pipeline and to accelerate our fast follower monoclonal antibody programs" said Sijmen de Vries, CEO of 4-Antibody AG.

Dr. Gerhard Ries, General Partner at BioMedPartners said: "4-Antibody has made a tremendous progress over the last two years and was able to achieve all scientific and business milestones. BioMedInvest is very happy to support the company and to participate in this financing round to accelerate the business activities of 4-Antibody."

Raj Parekh, General Partner at Advent Venture Partners commented: "The 4mAb™ technology has the potential to become an industry standard to increase the potency and specificity of human monoclonal antibodies designed for therapeutic use. We are very pleased to support the company."

### **About 4-Antibody AG**

4-Antibody AG is a Basel-based privately owned company, with a wholly owned subsidiary in Jena, Germany. 4-Antibody owns a novel and proprietary technology platform (4mAb™) for the development and/or optimization of fully human antibodies. For more information about 4-Antibody, please visit our website at: [www.4-antibody.com](http://www.4-antibody.com).

### **About BioMedPartners**

BioMedPartners is a leading independent European venture capital firm, providing private equity and mezzanine financing to early- to mid-stage healthcare and life-science companies. Since 2003, BioMedPartners has invested in nearly 20 highly innovative enterprises of which four already have successfully completed their IPO (Arpida AG, Santhera Pharmaceuticals AG) or have been acquired or merged with leading companies in the industry (Glycart Biotechnology AG, Carex AG). With more than CHF 150 million in capital under management and a strong team of experienced specialist with a broad expertise and an extensive scientific and financial network, BioMedPartners has established itself as one of the leading early-stage healthcare investors in Europe. For additional information please visit: [www.biomedvc.com](http://www.biomedvc.com)

### **About Advent Ventures**

Advent Ventures is one of the most experienced technology venture capital firms in the UK. Established in 1981 it invests in both the Life Science and Information and Communications

Technology sectors. Advent Ventures has over £500 million (US\$ 900m) under management from institutional investors across Europe and the USA. It has backed around 60 life science companies of which, to date, 19 have obtained public listings. Recent investments by the Advent Life Sciences team include Norwegian radiopharmaceuticals company, Algeta; the US speciality pharma company, CardioKine Inc; the US medical services company NeoGuide and UK-based Thiakis which develops hormone-based treatments for obesity. For additional information please visit: [www.adventventures.com](http://www.adventventures.com)

For further information, please contact:

**BioMedPartners**

Dr. Gerhard Ries, General Partner  
Elisabethenstrasse 23  
CH-4051 Basel

T: +41 61 270 3580

F: +41 61 270 3500

E: [ries@biomedvc.com](mailto:ries@biomedvc.com)

W: [www.biomedvc.com](http://www.biomedvc.com)